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Abstract: Background: Periodontal disease is a chronic inflammatory condition that affects supporting
tissues around teeth, resulting in periodontal tissue breakdown. If left untreated, periodontal disease
could have serious consequences; this condition is in fact considered as the primary cause of tooth
loss. Being highly prevalent among adults, periodontal disease treatment is receiving increased
attention from researchers and clinicians. When this condition occurs around dental implants,
the disease is termed peri-implantitis. Periodontal regeneration aims at restoring the destroyed
attachment apparatus, in order to improve tooth stability and thus reduce disease progression
and subsequent periodontal tissue breakdown. Although many biomaterials have been developed
to promote periodontal regeneration, they still have their own set of disadvantages. As a result,
regenerative medicine has been employed in the periodontal field, not only to overcome the drawbacks
of the conventional biomaterials but also to ensure more predictable regenerative outcomes with
minimal complications. Regenerative medicine is considered a part of the research field called tissue
engineering/regenerative medicine (TE/RM), a translational field combining cell therapy, biomaterial,
biomedical engineering and genetics all with the aim to replace and restore tissues or organs to their
normal function using in vitro models for in vivo regeneration. In a tissue, cells are responding to
different micro-environmental cues and signaling molecules, these biological factors influence cell
differentiation, migration and cell responses. A central part of TE/RM therapy is introducing drugs,
genetic materials or proteins to induce specific cellular responses in the cells at the site of tissue repair
in order to enhance and improve tissue regeneration. In this review, we present the state of art of gene
therapy in the applications of periodontal tissue and peri-implant regeneration. Purpose: We aim
herein to review the currently available methods for gene therapy, which include the utilization of
viral/non-viral vectors and how they might serve as therapeutic potentials in regenerative medicine
for periodontal and peri-implant tissues.
Keywords: periodontal disease; periodontal tissue regeneration; periodontal tissue engineering;
peri-implant disease; gene therapy; genetic vectors
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1. Introduction
1.1. Periodontitis and Peri-Implantitis
Periodontal disease is a common oral disease in humans [1]. Mostly it is characterized by a chronic
inflammatory reaction of periodontal tissues that leads to the destruction of the attachment apparatus
of the tooth, including alveolar bone, cementum, and the periodontal ligament (PDL) [2]. Periodontitis
is usually initiated as a response to bacteria colonizing the tooth surface and gingival crevice [3].
The majority of the destruction that occurs in the host periodontal tissues is immune-mediated and
inflammatory immune reactions are considered as a defense mechanism of the host to protect against
infections, however, the sustained release of inflammatory cytokines leads to gingival recession and
alveolar bone loss [1]. Furthermore, many factors have been suggested to contribute to the development
and the severity of periodontitis, including age, smoking, diet, hormone deficiencies, bacteria, diabetes,
obesity and epigenetics [4].
Similar to periodontitis, peri-implantitis is induced by most of the known periodontal pathogenic
microorganisms, resulting in an inflammatory lesion in the soft tissues surrounding dental implants [5].
Since the periodontal ligament (PDL) is absent around implants, peri-implant tissues are less
vascularized, and less immunologically protected, than the corresponding periodontal tissues. This is
suggested to contribute to a more rapid, extensive tissue destruction observed in peri-implantitis,
compared to cases of periodontitis [6].
1.2. Periodontal/Peri-Implant Tissue Regeneration
The fundamental goal of reconstructive periodontal/peri-implant therapy is to repair diseased
supporting tissues [2,7]. At present, regeneration of damaged or diseased periodontal/peri-implant
tissues mostly relies on the placement of bone grafts or bone substitutes in association with guided
tissue regeneration (GTR) technique [8]. Over the past decades many biomaterials such asautografts,
allografts, xenografts, cell occlusive barrier membranes, applications of autogenous and recombinant
growth and differentiation factors (eg, platelet rich plasma “PRP”, recombinant human platelet-derived
growth factor “rhPDGF”, recombinant human bone morphogenetic protein-2 “rhBMP-2”), and their
combinations have been developed and tested to regenerate periodontal tissues with varying degrees
of success [2]. Each technique and material has its own advantages thus far; the ability to regenerate
completely the damaged periodontal supporting structures has not been achieved in patients [2].
1.3. Tissue Engineering/Regenerative Medicine (TE/RM)
Tissue engineering/regenerative medicine (TE/RM) is an established research field combining cell
therapy, biomaterials, biomedical engineering and genetics all with the aim “to stimulate regeneration
of tissues and organs by either implanting biomaterials for in vivo regeneration or by constructing
substitutes in vitro” [9]. Mason and Dunnill (2008) described regenerative medicine as a therapy
replacing or regenerating human cells, tissues, or organs to restore or establish their normal function [10].
The correct proliferation, migration, and maturation of tissue cells are dependent on coordinated
interactions with soluble factors, cells, and extracellular matrix (ECM) [11]. In general terms, TE/RM
mimics the natural healing process to reconstruct or regenerate damaged tissue [12].
The primary goal of regenerative periodontal bioengineering is “to promote endogenous repair
mechanisms and functional regeneration through the delivery of key growth factors (GFs) or cytokines
that stimulate host cells to invade a tissue defect and direct robust extra cellular matrix synthesis
in vivo” [13]. Growth factors or morphogens play critical roles in regulating all the biological activities
of cells, such as migration, proliferation, differentiation, maturation, and apoptosis. The introduction
of recombinant human GFs and other proteins for regeneration has positively influenced the clinical
outcomes of existing regenerative procedures, although the outcomes are often unpredictable,
drawbacks always exist and the long-term safety data are not available with the current methods of
protein delivery methods [13,14].
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A major clinical challenge for TE/RM is the controlled and efficient delivery of GFs for repair of
multi-tissue interfaces due to rapid degradation of the proteins [15]. The biological activity of the GFs
that promote bone formation in vivo is limited by diffusion and degradation, leading to a short half-life.
Several materials, including hydroxyapatite, tri-calcium phosphate, demineralized bone matrices,
poly-lactic acid homo- and heterodimers, and collagen have been tested as carriers and delivery
vehicles for these factors in a sustained and appropriate manner, however, appropriate local delivery
still remains as a problem [16]. The main limitations of these delivery systems are inability to provide a
sustained, continuous release of GFs, biodegradability, inflammatory reaction, immunological rejection,
and possible transmission of disease [16]. In order to overcome these problems, alternative approaches
have been established such as gene therapy applications that utilize genes encoding GF proteins to
be delivered to the target cells [16]. As a summary, periodontal tissue engineering encloses three
approaches: (1) Protein-based therapy (delivery of GFs), (2) cell-based therapy (delivery of stem cells),
(3) gene-based therapy (delivery of genes) [12].
1.4. Rationale of Gene Therapy for Periodontal Tissue Engineering
Periodontal healing is dependent upon a sequence of associated events including cellular
proliferation, migration, and attachment to components of the extracellular matrix as well as organic
matrix synthesis and mineralization. The reconstruction of lost tissues including alveolar bone,
ligament and cementum remains clinically challenging because of the involvement of three tissue types
and the complexity of their relationship [17–19].
The goal of the tissue engineering strategies in the reconstruction of tissues in periodontal/implant
region is to regenerate functional tissue through a series of key events that occur during periodontal
tissue formation and growth, by means of delivering signaling molecules, cells, and scaffold/matrix
to periodontal defects [12]. TE/RM has been used in the periodontal field, with an overall aim to
overcome the drawbacks of the conventional biomaterials and recombinant proteins.
Basically, the general principles of healing observed in the turnover of healthy tissues can be also
applied to the healing processes that take place in periodontal tissues. The cellular and molecular
activities of the healing process of the lost tissues depend on the continuous interplay between growth
factors and cytokines for both initiation and regulation of the process [17,18]. Current evidence
demonstrated that appropriate presentation of selected multiple regulatory signals in terms of sufficient
retention and optimized dose are required for effective regeneration [13]. TE/RM can be applied
to enhance regeneration of the periodontal tissues, but in the case of growth factors, none of the
present regenerative strategies are able to overcome the problems with protein stability or mode of
delivery [13].
When applied topically, growth factors remain in the periodontal defect for a limited duration,
probably due to proteolytic breakdown, receptor-mediated endocytosis, and the solubility of the
delivery vehicle [19]. The main difficulties to overcome at the moment are the insufficient retention
of in vitro and in vivo GF bioactivities in sustained delivery vehicles and the control of possible
corresponding interactions among them when they are delivered in a single release platform [13].
Current tissue engineering approaches for therapeutic purposes typically involve one-time
delivery of single growth factors, and in order to overcome the problems involved in protein-based
approach, gene therapy has been developed which provides long-term exposure of multiple growth
factors to the wound and maintains constant protein levels at the site of the defect [11–13]. In gene
therapy approach, the delivery method can be tailored to the specific characteristics of the wound
site [2,11,13]. The infiltrating cells can uptake the genes and continuously produce the therapeutic
protein(s) in the local environment [8]. In brief, the rationale of delivery of the gene(s) encoding
for therapeutic molecules for periodontal tissue engineering applications depends on its therapeutic
strategy for directed, sustained and regulated protein expression [20].
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2. Gene Therapy
2.1. Definition and History
A gene is a distinct sequence of nucleotides forming the chromosome portion of a cell’s DNA or
chromosomal RNA. Genes are the smallest functional units of the genetic system with two main types
of function: Determining the structure of the thousands of different proteins that are present in the
human body and controlling where, when and in what quantity each protein is made [21].
The US Food and Drug Administration (FDA) defines gene therapy as products “that mediate
their effects by transcription and/or translation of transferred genetic material and/or by integrating
into the host genome and that are administered as nucleic acids, viruses, or genetically engineered
microorganisms. The products may be used to modify cells in vivo or transferred to cells ex vivo prior
to administration to the recipient”.
Some of the milestones in gene therapy are listed in Table 1 [22,23].
Table 1. Brief history of gene therapy.
1909- Wilhelm Johannsen introduced the term “gene”.
1928- Griffith performed the first experiment suggesting that bacteria are capable of transferring genetic
information through a process known as “transformation”.
1952- Zinder and Lederberg introduced the term “transduction” as a mechanism of genetic transfer.
1968- Rogers and Pfuderer demonstrated a proof of concept for virus-mediated gene transfer.
1972- Fiedman and Roblin suggested gene therapy for genetic diseases.
1988- The first officially approved clinical protocol to introduce a foreign gene into humans was approved by
the Recombinant DNA Advisory Committee (RAC).
1990- FDA approved the first time a gene therapy trial with a therapeutic attempt in humans.
1999- FDA restricted all clinical trials using gene therapy for nearly a decade because of the outcomes of the
first gene-therapy-based clinical trial on ADASCID (adenosine deaminase: severe combined immune
deficiency) as patients eventually developed leukemia (4/10).
2003- China became the first country to approve a gene therapy based product for clinical use.
2012- EMA (The European Medicines Agency) recommended for the first time a gene therapy product
(Glybera) for approval in the European Union.
December 2017- First FDA approval of an in vivo gene-therapy product, for Luxturna from
Spark Therapeutics.
August 2018- US National Institutes of Health advisory committee declared “gene therapies on recombinant
DNA”no longer need to be reviewed before clinic studies.
2.2. General Principles of Gene Therapy
The main concept of gene therapy is based on transferring of genetic information to target cells in
order to alter specific genes in individual’s cells to produce a desired therapeutic effect [2,21,24,25].
In general, the selected DNA/RNA fragment/gene containing instructions for making a useful protein
is packed within a vector, usually a virus, bacterium or plasmid [3,22].
2.3. DNA Versus RNA Delivery
Gene therapy is either viral or non-viral based on the vectors utilized for DNA delivery [3,22].
Viral gene therapy employs the inherent property of the virus to penetrate and insert DNA into the
cells [3]. This viral vector acts as a vehicle and once inside the cytoplasm of the cell, it is packed into a
vesicle. Later, this vesicle breaks down and releases the vector into the nucleus of the cell [22].
In the recent years, the concept of delivering mRNA (encoding therapeutic protein) has gained
significant interest to overcome some drawbacks of DNA-based therapies [26]. In fact, the concept is
very similar but instead of DNA, it is the RNA that encodes the target protein that is to be delivered.
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RNA, upon entry into cells, can get transcribed into the target proteins directly in the cytoplasm,
avoiding the need for nuclear entry [26].
RNA delivery therapies have several advantages over DNA delivery, such as having no risk of
insertional mutagenesis and not including complex steps. Thus, RNA delivery represents a powerful
molecular means to synthesize intra-cellular proteins. Major concerns for using mRNA over DNA
include its inherent instability and immunogenicity. RNA therapy requires some in vitro modifications
in order to mitigate these properties before it can be used for clinical applications [26].
3. Delivery Vehicles: Viral Versus Non-Viral Vectors
In brief, strategies to deliver DNA can be divided into viral transduction and non-viral transfection,
both of which can be performed in vivo/ex vivo [23]. Success of gene therapy mainly depends on the
vectors that deliver transgenes to the target cells in an efficient manner to ensure adequate levels and
duration of transgene expression [27,28].
Inadequacies of the vector are still one of this field’s key shortcomings and the selection of an
appropriate vector for gene transfer depends on a number of factors, including:(1) Duration of protein
expression (transient versus long term), (2) morphology of the target site, (3) route of gene delivery
(ex vivo vs. in vivo), (4) target cells (dividing versus non-dividing, ease of transduction, receptor
expression,) (5) desired temporal regulation of transgene expression (inducible versus constitutive),
and (6) maximum threshold of vector-induced immune response acceptable for the host [2,29].
An ideal vector should have high specificity and low toxicity but there is no ideal single vector
that can meet all needs for all tissues; in other words, different vectors are needed for different clinical
applications [21,29].
3.1. Viral Vectors
Gene transfer using a virus or viral vector is known as transduction. Viruses are parasitic
particles and are frequently used as the basis for vectors because of their natural ability of efficiently
infecting host cells with genetic sequences [28,29]. In general, the viral genome is based on DNA
or RNA, sheathed in a protein capsid, and in some cases enveloped by a phospholipid bilayer.
Viral vectors, acting as delivery vehicles, are capable of prolonged transgene expression and have
markedly higher transduction efficiency when compared to non-viral methods. Numerous viral vectors
with different advantages/disadvantages have been studied for gene therapy including adenovirus,
retrovirus, adenovirus-associated virus (AAV), lentivirus, vaccinia virus and herpes simplex virus.
The main features of these systems that are most commonly used in tissue engineering are listed in
Table 2 [2,24,29].
Table 2. The main features of viral vectors.
Virus
Characteristics Retrovirus Adenovirus Adeno-Associated Virus Lentivirus (HIV-1)
Viral genome RNA dsDNA ssDNA RNA
Immune response Low High Moderate Low
Transgene
expression Constitutitve Transient Constitutive/transient Constitutive
Immunogenicity Low High Moderate Moderate
Potential
pathogenicity Low Low None Low
Insertional
mutagenesis Yes No Yes/no No
dsDNA: double stranded DNA, ssDNA: single -stranded DNA [2,29].
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3.2. Non-Viral Vectors
Gene transfer using a non-viral vector is known as transfection. The main difference between
viral vectors and non-viral vectors is that the latter consist of naked oligomeric DNA or plasmid
DNA. The importance of the use of non-viral and safer viral vectors became clear in 1999 when the
first gene-therapy-based ADASCID (adenosine deaminase: a severe combined immune deficiency)
clinical trial, resulted in 4/10 patients developing leukemia. The cause was the new ADA gene being
incidentally inserted into the genome close to the site of a proto-oncogene [23].
Direct injection of naked plasmid DNA is a simple and safe approach for the local delivery of the
target gene to dividing and non-dividing cells [29]. Non-viral gene delivery can be classified as:
1-physical: Electroporation, sonoporation, magnetofection, electric field-induced molecular
vibration, optical transfection, particle guns, micro-injection methods, lipofection;
2- chemical: Carriers such as dextrans, proteins, artificial lipids, calcium phosphate and other
polymers as vectors [3,23,30].
Chemical non-viral vectors are biomaterials that can be organic (ranging from polyelectrolytes
such as polylysine to liposomes or micelles from cationic surfactants) or inorganic (calcium phosphate,
cadmium sulfide, carbon nanotubes, gold and iron oxide etc.). In general, these biomaterials are
positively charged in order to facilitate their entry through the plasma membrane of target cells
overcoming the negative charge of DNA that hinders their entrance [3]. Once inside the cell,
the DNA-chemical complex is processed in the endosome and/or lysosome and the DNA is released into
the cytoplasm translocating to the nucleus through the nuclear pores reaching the extra chromosomal
space, where the DNA acts as local protein machinery [3].
Non-viral gene delivery is an alternative to viral gene therapy, offering enormous advantages
such as: Low cost, proven safety, high DNA carrying capacity, and the possibility to produce artificial
vectors according to specific needs [23]. Lipofection is a popular transfection method in cell biology
and related research fields, in which vesicles of cationic lipids bind to DNA and positively charged
complexes bind to the cell surface followed by uptake into the cells. Even though lipofection leads
to a 5- to 100-fold increased transfection rate when compared with other chemical methods, it is not
suitable for most primary isolated cells [31]. Liposome-based DNA delivery is one of the first methods
to introduce exogenous DNA into eukaryotic cells, but this method is hardly used in the field of bone
tissue engineering. This is possibly due to the fact that lipoplexes are cytotoxic at higher concentrations
because they are able to interact with and destabilize the cell membrane [23].
The limitations of non-viral gene delivery can be listed as: Low transfection efficiency, transient
expression, and non-selective cell targeting [30].
The successful transfection of cells by non-viral vectors depends on the preparation, purification,
composition, size and stability of the DNA-vector complex, its solubility in the endosome and the
endosomal escape to the nucleus [3,23]. Current advances in biomaterials and nanotechnology have
allowed researchers to produce non-viral vectors to target specific cells with an efficacy comparable to
viral vectors [31].
3.3. Inducible Systems for Viral Delivery
These systems typically use inducible promoters regulated by engineered and/or non-mammalian
transcription factors in order to control transgene expression. The activity of these transcription factors
is controlled by exogenous chemical agents such as tetracycline, which permit (“on” state) or repress
(“off” state) transgene expression [29,32].
3.4. Exosomes
Exosomes are extracellular vesicles of endocytic origin secreted by cells, with a size range between
30 and 100 nm [33] that carry macromolecules including lipids, proteins, and nucleic acids (mainly
RNA) [34].
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Unlike other gene delivery vectors, exosomes are rapidly taken up by target cells and have a
robust exosomal membrane that protects the RNA/gene of interest from digestion making them a more
efficient vehicle for gene delivery [35].
There are two mechanisms by which exosomes function: (1) Secreted exosomes can selectively
bind to cell surface receptors presented by recipient cells, resulting in the transduction of specific
intracellular signaling and a subsequent induction of physiological changes in the recipient cells [36],
(2) secreted exosomes can directly transfer intra-exosomal content such as mRNA and microRNA
inside the recipient cells by fusion with cell membranes [37].
4. Route of Gene Delivery: Ex Vivo Versus In Vivo
In vivo gene delivery is a one-step process that may be necessary for disorders requiring immediate
treatment (Figure 1). One of main challenges of this approach is low transduction efficiency and the
possibility of causing inflammatory/immune response. Another limitation is the difficulty in targeting
the cell population of interest [29].
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hile in ex vivo gene transfer, the foreign gene is transduced into the cells of a tissue biopsy,
followed by genetic modification of these cells under in vitro conditions (Figure 2). After this preparation
phase outside the body, these cells are subsequently implanted into the site of injury [21,29].
Delivery by ex vivo gene vehicle can be considered as a safer method, because cells can be screened
for tumorigenicity before implantation into the host. However, these initial steps are often labor
intensive, complex and involve significant cost [29].
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5. Gene Therapy Applications for Periodontal Tissue Engineering
5.1. Adenovirus Vectors (AV)
Bone morphogenetic proteins (BMPs) have great potential in the regeneration of periodontal
tissues. Limitations of BMP administration to periodontal lesions include their transient biological
activity, and low bioavailability at the wound site. Gene transfer might serve as an alternative treatment
strategy to deliver BMPs to periodontal tissues [38,39].
In 2003, Jin et al. tested adenoviral vectors for ex vivo BMP-7 and noggin gene transfer in
order to stimulate tissue engineering in large mandibular bone defects in rats [38]. Noggin is an
antagonist of BMP bioactivity that binds to selected BMPs and blocks the binding of BMP-2, -4, and -7
to cell surface receptors. The osseous lesions treated by AV/BMP-7 gene delivery demonstrated
rapid chrondrogenesis, with subsequent osteogenesis, cementogenesis and predictable bridging of the
periodontal bone defects. The results of this experiment demonstrated the first successful evidence of
periodontal tissue engineering using ex vivo gene transfer of BMPs [38]. In a similar study, in 2004,
the same research group tested the effect of BMP-7 and noggin gene transfer in a severe combined
immunodeficient (SCID) mice model [39].
Cloned murine cementoblast cells (OCCM) were transduced using adenoviruses encoding BMP-7
and were seeded into polymer scaffolds. These 3D scaffolds were implanted into SCID mice to determine
the in vivo mineral-inducing ability of the cells in mature cementoblast populations. The results of
this study indicated that gene transfer of noggin inhibits biomineralization induced by cementoblasts
and exogenous BMP has minimal effects on mineralization [39]. The potential of chitosan/collagen
scaffold combined AV/BMP-7 was also evaluated for regeneration of the mandibular defects in dogs
with beneficial results [40].
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Chen et al. evaluated regeneration of the periodontal attachment apparatus in a rabbit study,
using a combination of ex vivo autologous bone marrow mesenchymal stem cells (MSCs) and AV for
BMP-2 gene delivery. Their results indicated that ex vivo gene transfer using stem cells as vectors
may provide an advantage of slower BMP-2 release, increasing cementogenesis [8]. In a similar
study, ex-vivo AV/BMP-2 gene delivery using canine periodontal ligament stem cells (PDLSCs) for
regeneration of peri-implantitis defects in dogs were tested. In conclusion, ex vivo BMP2 gene delivery
using PDLSCs enhanced new bone formation and re-osseointegration in peri-implantitis defects [6].
Polypeptide growth factors, such as platelet-derived growth factors (PDGFs), stimulate both
cementogenesis and osteogenesis. Platelet-derived growth factors (PDGFs) also exert potent effects on
wound healing including the regeneration of tooth-supporting structures. Recent advances in gene
therapy offer the advantage of delivering recombinant proteins to tissues for extended periods of time
in vivo [19].
In 2003, Anusaksathein et al. tested the effect of Adenovirus/PDGF-A and -B delivery to human
gingival fibroblasts (HGFs) on ex vivo repair in three-dimensional collagen lattices. According to their
results, PDGF gene transfer has potential for periodontal soft tissue-engineering applications [41].
A year later, the same research group published another paper on immortalized cementoblast cells
(OCCM) transduced with AV for PDGF-A gene delivery in a SV40 transgenic mice model. Their findings
suggested that continuous exogenous delivery of PDGF-A might delay mineral formation induced by
cementoblasts, while PDGF is clearly required for mineral neogenesis [42]. The effects of gene transfer
by AV/PDGF-B on human gingival fibroblasts (HGFs) and the subsequent regulation of genes and
cell-surface proteins associated with cellular signaling was also evaluated in an in vitro study [43].
The findings of this study demonstrated that AV/PDGF-B gene delivery displays sustained signal
transduction effects in human gingival fibroblasts [43].
Recently, the roles of the hepatocyte growth factor (HGF) associated with human dental pulp
stem cells (DPSCs) in periodontal tissue regeneration were also investigated. According to the results,
adenovirus-mediated transfer of hepatocyte growth factor gene to human dental pulp stem cells
improved the potential for periodontal regeneration in swine model [44].
5.2. AAV (Adeno-Associated Viral Vectors)
Adeno-associated viral vectors are derived from a replication-deficient, non-pathogenic parvovirus
with a single-stranded DNA genome and they are particularly efficient in transduction of non-dividing
cells [45].
AAVs have been proposed as gene delivery vector to prevent periodontal disease progression in
rats. Cirelli et al. (2009) demonstrated the use of pseudotyped adeno-associated virus vector based
on serotype 1 (AAV2/1) to deliver TNF receptor-immunoglobulin Fc (TNFR:Fc) to rats subjected to
Porphyromonas gingivalis (P.g.) [46]. The results of this study showed that AAV2/1-TNFR:Fc led to
potent inhibition of periodontal disease progression [46]. In a similar study, Jiang et al. evaluated
AAV-mediated RNAi knockdown (sh) of Atp6i/TIRC7 gene expression to treat periodontal disease.
Mice were infected with P. gingivalis W50 in the maxillary periodontium to induce periodontitis.
The results suggested that AAV-shRNA-Atp6i/TIRC7 therapeutic treatment might significantly improve
the health of patients who suffer from P. gingivalis-mediated periodontal disease [47].
In a more recent in vivo experiment on mice, the role of cathepsin K (Ctsk) in chronic periodontal
infection and inflammation was investigated. For this purpose, the animals were infected with
P. gingivalis and small hairpin (sh)RNA (AAV-sh-Ctsk) was used to silence cathepsin K. According to
the results, AAV-mediated silencing of Ctsk efficiently protected the animals against periodontal tissue
damage and alveolar bone loss [48].
The ability of human osteoprotegerin (hOPG) recombinant adenovirus
Ad5-hOPG-EGFP-transfected periodontal ligament cells (PDLCs) and BME-10X collagen membranes
in combination with cell transplantation, to promote periodontal regeneration, was evaluated by Jiang
et al. in 2016. The radiographic and histological results suggested that hOPG-PDLCs significantly
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promoted periodontal defect repair in beagle dogs. As a conclusion, this study demonstrated the
potential of hOPG-modified PDLCs for periodontal tissue regeneration [49].
5.3. rAds (Recombinant Adeno-Viral) Vectors
The wild-type adenoviruses, including human adenovirus type 5, are associated with a number of
mild disorders, such as respiratory infections. Recombinant adeno-associated virus (rAds) is a purified
replication of a human parvovirus allowing it to safely be used as a gene delivery tool. rAds have
been used as gene delivery vectors because of several unique features: (1) Ads have high transduction
efficiency in both dividing and non-dividing cells; (2) Ads do not induce apparent phenotypic changes
in transduced cells; and (3) Ads do not integrate into the host genome and remain episomal [19].
Giannobile et al. (2001) tested recombinant adenoviral vectors (rAds) encoding for the
platelet-derived growth factor: A gene delivery of PDGF transgenes to cells to promote periodontal
tissue regeneration. The findings demonstrated that sustained PDGF gene delivery stimulated
cementoblast activity in vitro. As a conclusion, it was stated that this therapy might offer the
advantage of delivering recombinant proteins to tissues for extended periods of time in vivo as a
novel approach to periodontal tissue engineering [19]. In a similar in vitro experiment Zhu et al.
evaluated ex-vivo-transfection of rAds (Ad2) encoding PDGF-A or PDGF-1308 to cells derived from
the periodontium. As a result, it was reported that Ad2/PDGF effectively transduced cells derived
from the periodontium and promoted biological activity. This study supports the potential use of gene
therapy for sustained PDGF release in periodontal tissues [50].
In 2005, in vivo gene delivery using rAds encoding either the BMP-7 or the luciferase gene- using
a collagen matrix was also tested. Treatment of dental implant fixtures with Ad/BMP-7 resulted in
enhancement of alveolar bone defect fill, coronal new bone formation, and new bone-to-implant
contact [51]. The results revealed sustained, targeted transgene expression for up to 10 days at the
osteotomy sites with nearly undetectable levels by 35 days. As a conclusion, in vivo gene therapy
of BMP-7 offers potential for alveolar bone engineering applications [51]. As a conclusion, results
generated from these studies showed the effective transduction of the recombinant adenoviruses to the
cells derived from periodontal tissues with corresponding positive effects on the modulation of DNA
synthesis and cell proliferation [51].
5.4. Lentiviral Vectors
Lentiviral transfection was used by Xiang et al. to investigate follicular dendritic cell secreted
protein (FDC-SP) on the inhibition of osteogenic differentiation of human PDL cells (hPDLCs).
Their findings demonstrated that transfection with FDC-SP has a negligible adverse effect on
proliferation of hPDLCs and implied the biological function of FDC-SP as a fibroblastic phenotype
stabilizer by inhibiting hPDLCs differentiation into mineralized tissue-forming cells, thus regulating
periodontal tissue regeneration [52].
In another in vitro experiment the role of the ephrinB2/EphB4 signaling pathway in regulating
osteogenic differentiation of periodontal ligament stem cells (PDLSCs) and crosstalk between PDLSCs
and pre-osteoblasts within co-culture was investigated through ephrinB2 transgenic expression
in PDLSCs [53]. The human EFNB2 transgenic lentivirus PDLSCs isolated from premolar teeth
were transfected with transgenic (hEfnB2-GFP-Bsd) vector or empty vector (GFP-Bsd). The data
indicated that transgenic expression of ephrinB2 in PDLSCs (periodontal ligament stem cell) could
promote osteogenic differentiation via stimulation of the phosphorylation of ephrinB2 and EphB4,
which regulates cell communication between PDLSCs and pre-osteoblasts within the co-culture. As a
result, recombinant overexpression of ephrinB2 in PDLSCs enhanced osteogenic differentiation of
pre-osteoblasts [53].
Lentivirus vectors represent a potential of transducing many forms of non-dividing cells [54].
Lentiviral-based gene delivery can be an appropriate strategy for alveolar bone repair applications
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requiring sustained, long-term expression of therapeutic proteins but they also have some safety
issues [29].
5.5. Non-Viral Vectors
Non-viral vectors are exciting alternatives devoid of all the drawbacks associated with viral vectors
such as immunological concerns. They typically consist of plasmid DNA alone or in combination with
a carrier (e.g., liposomes, cationic polymers, porous scaffolds) [29].
Elangovan et al. (2013) evaluated PDGF-B plasmids gene delivery in fibroblasts using nanosized
calcium phosphate particles (NCaPP-PDGF-B) as vectors for periodontal regeneration. As a conclusion,
significantly enhanced fibroblast proliferation, observed in NCaPP-PDGF-B–treated cells, confirmed
the functionality of these nanoplexes [31].
In another study, transfection efficiency and toxicity of non-viral-gene-transfer methods and
lentiviral vectors on human periodontal-ligament-stem-cells (hPDLSCs) were compared. The hPDLSCs
were transfected by (1) Lipofectamine 2000, (2) polyethylenimine, (3) GBfectene-Elite transfection
reagent, (4) X-tremeGENE HP DNA transfection reagent, and (5) magnet-assisted transfection (MATra),
compared to (6) lentiviral vectors harboring a green-fluorescent-protein gene.
The transfection efficiency was measured by a fluorescence microscope and flow cytometry.
Meanwhile, the cell morphology and growth status were observed to estimate the cytotoxicity.
The transfection efficiency of hPDLSCs with MATra was higher than the other non-viral transfection
reagents in this study, but it was far less than the lentiviral vectors [55].
5.6. The Gene-Activated Matrix (GAM)
The gene-activated matrix (GAM) technology is a direct gene transfer strategy, blending the
two strategies—tissue engineering and local gene delivery system in periodontal tissue regeneration.
GAM serves as a local bioreactor with therapeutic gene expression and provides a structural template
to fill the lesion defects for cell adhesion, proliferation and synthesis of the extracellular matrix (ECM).
When GAM is implanted into a tissue defect, granulation tissue fibroblasts proliferate and migrate
into the GAM and take up and transiently express the therapeutic gene, thereby promoting tissue
regeneration [56].
Although a number of studies focused on the safety profile of adenovirus-mediated gene therapy,
few of them have addressed the local delivery of AVVs using a gene-activated matrix. Chang et al. (2009)
tested local administration of AVV encoding human PDGF-B with a gene-activated collagen matrix [57].
Their results indicated that DNA vector- E1-, E3-deleted human adenovirus serotype 5 vectors are a
safe method when delivered to tooth-supporting alveolar bone defects. No treatment-related toxicity
or systemic involvement was found and these results support the further clinical development of
AV/PDGF-B for regeneration therapy for oral and craniofacial bone applications [57].
In vitro plasmid DNA non-viral delivery, using GAM with embedded chitosan/plasmid
nanoparticles encoding platelet derived growth factor (PDGF) based on porous chitosan/collagen
composite scaffold was evaluated by Peng et al. in 2009 [56]. In this experiment, the chitosan/collagen
scaffold acted as a three-dimensional carrier and chitosan nanoparticles condensed plasmid DNA.
The plasmid DNA entrapped in the scaffolds showed a sustained and steady release over six weeks.
MTT assay (colorimetric assay for assessing cell metabolic activity) demonstrated that periodontal
ligament cells (PDLCs) cultured into the novel GAM achieved high proliferation. The histological
results confirmed the periodontal connective tissue-like structure formation in the scaffolds after
two weeks. As a result, it can be concluded that the novel GAM has potential in the application of
periodontal tissue engineering [56].
In 2013, Yang et al. evaluated the effect of combining Bio-Oss (collagen bone graft material)
with bone marrow stromal cells (BMSCs) transfected with the basic fibroblast growth factor (bFGF)
gene-encoding plasmids on bone regeneration during mandibular distraction in rabbits [58]. According
to the results of this study, bFGF promoted proliferation and differentiation of BMSCs in vitro and
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implantation of bFGF-expressing BMSCs combined with Bio-Oss enhanced new bone regeneration
in vivo more effectively than traditional methods [58].
GAMs delivering polyplexes of polyethylenimine (PEI)-plasmid DNA (pDNA) encoding
recombinant human platelet-derived growth factor-BB (rhPDGF-BB) were evaluated for promotion
of periodontal wound repair in rodents [59]. Defects treated with sustained PDGF gene delivery
demonstrated delayed healing coupled with sustained inflammatory cell infiltrates lateral to the
osseous defects. Furthermore, significantly greater osteogenesis was observed for collagen-alone
and rhPDGF-BB versus the PEI-containing groups. This non-viral gene delivery system appeared to
prolong inflammatory response, slowing alveolar bone regeneration in vivo [59].
5.7. Bubble Liposomes and Ultrasound for Gene Delivery
Sugano et al. compared delivery of naked plasmid DNA-encoding luciferase or enhanced green
fluorescent protein (EGFP) into the lower labial gingiva of Wistar rats using bubble liposomes, with or
without ultrasound exposure [60]. Previously, they developed bubble liposomes as a useful carrier
for gene or drug delivery, and reported that delivery efficiency was increased with high frequency
ultrasound in vitro and in vivo. Hence, the aim was to examine the possibility of delivering genes into
gingival tissues using bubble liposomes and ultrasound. As a conclusion, the combination of bubble
liposomes and ultrasound provided an efficient technique for delivering plasmid DNA into the gingiva
and bubble liposomes can be considered as a useful carrier for gene or drug delivery. This technique
can be applied for the delivery of a variety of therapeutic molecules into target tissue, and in the future
may serve as a useful treatment strategy for periodontitis [60].
6. Future Perspectives
The complexity of gene-enhanced periodontal regenerative therapeutics lies in determining
which gene or gene combinations are necessary and sufficient to enhance the multiple tissue types
regeneration in the periodontium. In the future, it might be possible to mimic the natural healing
process by developing novel biomimetic scaffolds that react to environmental stimuli or release their
cargo (proteins or genes) according to individual cellular demand. Co-operation between tissue
engineers and periodontal clinicians may eventually help to overcome the challenges [13].
Scaffolds form an important component of the periodontal regenerative armamentarium [61,62]
and it is expected in the near future that the use of gene-activated scaffolds, from pre-clinical studies to
the clinics, will be easily accepted not only by the patients but also by the dental community, owing to
its long history of acceptance. It is also expected that the cost of manufacturing such non-viral gene
delivery systems will decrease, allowing treatment for a vast majority of patients [13,63].
Although gene therapy to enhance periodontal regeneration is still at a primitive stage, the constant
growth in the development of non-viral vectors with better transfection efficiency suggests that
DNA-based therapeutics may play a significant role in periodontal regeneration in the coming years [3].
7. Conclusions
The choice of vector for gene therapy depends upon a number of factors, and these parameters vary,
depending upon the nature of the disease or condition to be treated. One of the main factors is the need
to achieve the required level and duration of transgene expression. As an example, a genetic disease
is likely to require life-long expression of a transgene, while healing of a periodontal tissue would
only requires transient expression of suitable growth factors [27]. Each vector has different features,
advantages and disadvantages among them. Retroviral vectors efficiently transduce dividing cells
and achieve sustained and efficient transgene expression that can be propagated in target cells during
mitotic division [27,29]. However, they cause insertional mutagenesis, so their clinical applications are
limited just to life-threatening diseases [64].
The adenovirus vector (AV) is the most investigated viral vector in periodontal tissue regeneration
procedures. AVs have highly evolved mechanisms for DNA delivery. They are not dependent on cell
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replication to infect cells and this leads to a high level of gene expression. AVs can infect a broad range
of cell types and can be purified in high titers. They are also considered as non-oncogenic [39].
However, according to the preclinical results, AVs are inadequate for long term, stable gene
expression. Another major consideration regarding using adenovirus in gene transfer procedures
is the significant cytotoxic T-cell-mediated immune response that occurs when they are delivered
in vivo. Studies have shown that direct systemic administration of adenoviral vectors can result in
acute toxicity and hepatic pathology [28,39].
The major limitation for the use of adenoviral vectors is their high immunogenicity, which may
cause inflammation, curtail transgene expression and interfere with repeated dosing [28]. When clinical
translation is intended, factors such as safety, cost and intellectual property become a crucial concern
for the safety of adenoviral vectors [23,29].
Second generation AVs were developed to overcome these limitations. They do not have viral
proteins or genes and they are considered as less immunogenic than the first generation of AVs. Due to
the lack of genes/viral proteins, second generation AVs can be generated just in the presence of helper
viruses that contain the missing viral genes necessary to form a viable capsid [13].
The adeno-associated viral vector (AAV) is non-pathogenic, non-immunogenic, and able to infect
a wide variety of dividing and non-dividing cells. AAVs are non-enveloped parvoviruses with the
ability to transiently infect target cells, which minimizes the risk of insertional mutagenesis. For these
reasons, adenoviral gene delivery has been used more extensively and safely for in vivo approaches
than retroviral-based systems, but their restricted tropism and their relatively small capacity for foreign
DNA have limited their use [29].
Although viral approaches have many advantages, such as prolonged transgene expression and
high transduction efficiency, their perceived safety concerns poses a challenge for human translation
for treatment of non-life-threatening conditions [59]. As an alternative, non-viral gene delivery systems
could overcome this barrier.
These non-viral vectors may be advantageous because of their good bioavailability, low cost,
and low immunogenicity due to the absence of viral proteins. They also have the ability to carry
large DNA segments, and cause minimal induction of host immune responses [27,29,59]. However,
non-viral vectors are far less efficient than viral vectors, although proper selection and optimization of
vector-to-DNA ratio significantly enhances non-viral transfection efficiency [27,59,65].
As a conclusion, gene therapy can be considered as an alternative, which can overcome the
common drawbacks of growth factors. Although current gene delivery approaches are reliable
and consistent in terms of their transduction/transfection efficiency showing promising results in
periodontal tissue regeneration, difficulty still exists in translating this technology to treat humans in
clinics [13,26,50].
Fundamental questions that must be rigorously addressed are the selection of the suitable genes
to target and employing safe vectors in order to develop a practical therapeutic modality that is both
effective and safe [47]. Although gene transfer methods may circumvent many of the limitations within
alternative protein delivery, current research so far provides insufficient data to permit definitive
comparison [2].
Author Contributions: Conceptualization, F.G., F.A. and L.L.; Methodology, F.G. and F.A.; Validation, F.G.,
F.A., M. D.F. and L.L.; Formal Analysis, F.G.; Resources, F.G. and F.A.; Writing-Original Draft Preparation, F.G.;
Writing-Review & Editing, F.G., F.A., M.D.F. and L.L.; Supervision, M.D.F. and L.L.; Project Administration, F.G.
and F.A.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest
Int. J. Mol. Sci. 2019, 20, 3551 14 of 16
References
1. Liu, Z.; Chen, X.; Zhang, Z.; Zhang, X.; Saunders, L.; Zhou, Y.; Ma, P.X. Nanofibrous Spongy Microspheres to
Distinctly Release miRNA and Growth Factors to Enrich Regulatory T Cells and Rescue Periodontal Bone
Loss. ACS. Nano. 2018, 12, 9785–9799. [CrossRef] [PubMed]
2. Ramseier, C.A.; Abramson, Z.R.; Jin, Q.; Giannobile, W.V. Gene Therapeutics for Periodontal Regenerative
Medicine. Dent. Clin. N. Am. 2006, 50, 245–263. [CrossRef]
3. Elangovan, S.; Karimbux, N. Review Paper: DNA Delivery Strategies to Promote Periodontal Regeneration.
J. Biomater. Appl. 2010, 25, 3–18. [CrossRef] [PubMed]
4. Larsson, L. Current Concepts of Epigenetics and Its Role in Periodontitis. Curr. Oral Health Rep. 2017, 4,
286–293. [CrossRef] [PubMed]
5. Colombo, A.P.V.; Tanner, A.C.R. The Role of Bacterial Biofilms in Dental Caries and Periodontal and
Peri-implant Diseases: A Historical Perspective. J. Dent. Res. 2019, 98, 373–385. [CrossRef]
6. Park, S.Y.; Kim, K.H.; Gwak, E.H.; Rhee, S.H.; Lee, J.C.; Shin, S.Y.; Koo, K.T.; Lee, Y.M.; Seol, Y.J. Ex vivo bone
morphogenetic protein 2 gene delivery using periodontal ligament stem cells for enhanced re-osseointegration
in the regenerative treatment of peri-implantitis. J. Biomed. Mater. Res. Part A. 2015, 103, 38–47. [CrossRef]
[PubMed]
7. Taba, M., Jr.; Jin, Q.; Sugai, J.V.; Giannobile, W.V. Current concepts in periodontal bioengineering.
Orthod. Craniofac. Res. 2005, 8, 292–302. [CrossRef]
8. Chen, Y.L.; Chen, P.K.; Jeng, L.B.; Huang, C.S.; Yang, L.C.; Chung, H.Y.; Chang, S.C. Periodontal regeneration
using ex vivo autologous stem cells engineered to express the BMP-2 gene: An alternative to alveolaplasty.
Gene Ther. 2008, 15, 1469–1477. [CrossRef] [PubMed]
9. Brouwer, K.M.; Lundvig, D.M.; Middelkoop, E.; Wagener, F.A.; Von den Hoff, J.W. Mechanical cues in
orofacial tissue engineering and regenerative medicine. Wound Rep. Reg. 2015, 23, 302–311. [CrossRef]
10. Mason, C.; Dunnil, P. A brief definition of regenerative medicine. Regen. Med. 2008, 3, 1–5. [CrossRef]
11. Chen, F.M.; An, Y.; Zhang, R.; Zhang, M. New insights into and novel applications of release technology for
periodontal reconstructive therapies. J. Control. Release 2011, 149, 92–110. [CrossRef] [PubMed]
12. Abbayya, K.; Zope, S.A.; Naduwinmani, S.; Pisal, A.; Puthanakar, N. Cell- and Gene- Based therapeutics for
periodontal regeneration. Int. J. Prev. Med. 2015, 6, 110. [CrossRef] [PubMed]
13. Chen, F.M.; Ma, Z.W.; Wang, Q.T.; Wu, Z.F. Gene Delivery for Periodontal Tissue Engineering: Current
Knowledge—Future Possibilities. Curr. Gene Ther. 2009, 9, 248–266. [CrossRef] [PubMed]
14. Kaigler, D.; Cirelli, J.A.; Giannobile, W.V. Growth factor delivery for oral and periodontal tissue engineering.
Expert Opin. Drug Deliv. 2006, 3, 647–662. [CrossRef] [PubMed]
15. Hao, J.; Cheng, K.C.; Kruger, L.G.; Larsson, L.; Sugai, J.V.; Lahann, J.; Giannobile, W.V. Multigrowth Factor
Delivery via Immobilization of Gene Therapy Vectors. Adv. Mater. 2016, 16, 3145–3151. [CrossRef] [PubMed]
16. Fischer, J.; Kolk, A.; Wolfart, S.; Pautke, C.; Warnke, P.H.; Plank, C.; Smeets, R. Future of local bone
regeneration—Protein versus gene therapy. J. Craniomaxillofac. Surg. 2011, 39, 54–64. [CrossRef] [PubMed]
17. Bartold, P.M.; Narayanan, A.S. Molecular and cell biology of healthy and diseased periodontal tissues.
Periodontol. 2000 2006, 40, 29–49. [CrossRef] [PubMed]
18. Polimeni, G.; Xiropaidis, A.V.; Wikesjö, U.M. Biology and principles of periodontal wound
healing/regeneration. Periodontol. 2000 2006, 41, 30–47. [CrossRef]
19. Giannobile, W.V.; Lee, C.S.; Tomala, M.P.; Tejeda, K.M.; Zhu, Z. Platelet-Derived Growth Factor (PDGF) Gene
Delivery for Application in Periodontal Tissue Engineering. J. Periodontol. 2001, 72, 815–823. [CrossRef]
20. Chang, P.C.; Seol, Y.J.; Cirelli, J.A.; Pellegrini, G.; Jin, Q.; Franco, L.M.; Goldstein, S.A.; Chandler, L.A.; Barbara
Sosnowski, B.; Giannobile, W.V. PDGF-B Gene Therapy Accelerates Bone Engineering and Oral Implant
Osseointegration. Gene Ther. 2010, 17, 95–104. [CrossRef]
21. Prabhakar, A.R.; Paul, J.M.; Basappa, N. Gene Therapy and its Implications in Dentistry. Int. J. Clin. Pediatr.
Dent. 2011, 4, 85–92. [CrossRef]
22. Wirth, T.; Parker, N.; Ylä-Herttuala, S. History of gene therapy. Gene 2013, 525, 162–169. [CrossRef]
23. Wegman, F.; Oner, F.C.; Dhert, W.J.; Alblas, J. Non-viral gene therapy for bone tissue engineering. Biotechnol.
Genet. Eng. Rev. 2013, 29, 206–220. [CrossRef]
24. Ramseier, C.A.; Rasperini, G.; Batia, S.; Giannobile, W.V. Advanced regenerative technologies for periodontal
tissue repair. Periodontol. 2000 2012, 59, 185–202. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3551 15 of 16
25. Amuk, N.G.; Kurt, G.; Baran, Y.; Seyrantepe, V.; Yandim, M.K.; Adan, A.; Demir, S.A.; Kiraz, Y.;
Sonmez, M.F. Effects of cell-mediated osteoprotegerin gene transfer and mesenchymal stem cell applications
on orthodontically induced root resorption of rat teeth. Eur. J. Orthod. 2017, 39, 235–242. [CrossRef]
26. Elangovan, S.; Kormann, M.S.; Khorsand, B.; Salem, A.K. The Oral and Craniofacial Relevance of Chemically
Modified RNA Therapeutics. Discov. Med. 2016, 21, 35–39.
27. Evans, C. Gene therapy for the regeneration of bone. Injury 2011, 42, 599–604. [CrossRef]
28. Evans, C. Gene delivery to bone. Adv. Drug Deliv. Rev. 2012, 64, 1331–1340. [CrossRef]
29. Phillips, J.E.; Gersbach, C.A.; Garcia, A.J. Virus-based gene therapy strategies for bone regeneration.
Biomaterials 2007, 28, 211–229. [CrossRef]
30. Kaestner, L.; Scholz, A.; Lipp, P. Conceptual and technical aspects of transfection and gene delivery.
Bioorg. Med. Chem. Lett. 2015, 25, 1171–1176. [CrossRef]
31. Elangovan, S.; Jain, S.; Tsai, P.C.; Margolis, H.C.; Amiji, M. Nano-Sized Calcium Phosphate Particles for
Periodontal Gene Therapy. J. Periodontol. 2013, 84, 117–125. [CrossRef]
32. Gossen, M.; Bujard, H. Studying gene function in eukaryotes by conditional gene inactivation. Annu. Rev.
Genet. 2002, 36, 153–173. [CrossRef]
33. Pan, B.T.; Johnstone, R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro:
Selective externalization of the receptor. Cell 1983, 33, 967–978. [CrossRef]
34. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of
mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9,
654–659. [CrossRef]
35. Mathiyalagan, P.; Sahoo, S. Exosomes-Based GeneTherapyfor MicroRNA Delivery. Methods Mol. Biol. 2017,
1521, 139–152.
36. Thery, C.; Ostrowski, M.; Segura, E. Membrane vesicles as conveyors of immune responses. Nat. Rev.
Immunol. 2009, 9, 581–593. [CrossRef]
37. Parolini, I.; Federici, C.; Raggi, C.; Lugini, L.; Palleschi, S.; De Milito, A.; Coscia, C.; Iessi, E.; Logozzi, M.;
Molinari, A.; et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem.
2009, 284, 34211–34222. [CrossRef]
38. Jin, Q.M.; Anusaksathien, O.; Webb, S.A.; Rutherford, R.B.; Giannobile, W.V. Gene Therapy of Bone
Morphogenetic Protein for Periodontal Tissue Engineering. J. Periodontol. 2003, 74, 202–213. [CrossRef]
39. Jin, Q.M.; Zhao, M.; Economides, A.N.; Somerman, M.J.; Giannobile, W.V. Noggin Gene Delivery Inhibits
Cementoblast-Induced Mineralization. Connect Tissue Res. 2004, 45, 50–59. [CrossRef]
40. Zhang, Y.; Song, J.; Shi, B.; Wang, Y.; Chen, X.; Huang, C.; Yang, X.; Xu, D.; Cheng, X.; Chen, X. Combination
of scaffold and adenovirus vectors expressing bone morphogenetic protein-7 for alveolar bone regeneration
at implant defects. Biomaterials 2007, 28, 4635–4642. [CrossRef]
41. Anusaksathien, O.; Webb, S.A.; Jin, Q.M.; Giannobile, W.V. Platelet-derived growth factor gene delivery
stimulates ex vivo gingival repair. Tissue Eng. 2003, 9, 745–756. [CrossRef]
42. Anusaksathien, O.; Jin, Q.; Zhao, M.; Somerman, M.J.; Giannobile, W.V. Effect of sustained gene delivery of
platelet-derived growth factor or its antagonist (PDGF-1308) on tissue-engineered cementum. J. Periodontol.
2004, 75, 429–440. [CrossRef]
43. Lin, Z.; Sugai, J.V.; Jin, Q.; Chandler, L.A.; Giannobile, W.V. Platelet-derived growth factor-B gene delivery
sustains gingival fibroblast signal transduction. J. Periodontal Res. 2008, 43, 440–449. [CrossRef]
44. Cao, Y.; Liu, Z.; Xie, Y.; Hu, J.; Wang, H.; Fan, Z.; Zhang, C.; Wang, J.; Wu, C.T.; Wang, S. Adenovirus-mediated
transfer of hepatocyte growth factor gene to human dental pulp stem cells under good manufacturing
practice improves their potential for periodontal regeneration in swine. Stem Cell Res. Ther. 2015, 6, 249.
[CrossRef]
45. Warrington, K.H., Jr.; Herzog, R.W. Treatment of human disease by adeno-associated viral gene transfer.
Hum. Genet. 2006, 119, 571–603. [CrossRef]
46. Cirelli, J.A.; Park, C.H.; MacKool, K.; Taba, M., Jr.; Lustig, K.H.; Burstein, H.; Giannobile, W.V. AAV2/1-TNFR:Fc
gene delivery prevents periodontal disease progression. Gene Ther. 2009, 16, 426–436. [CrossRef]
47. Jiang, H.; Chen, W.; Zhu, G.; Zhang, L.; Tucker, B.; Hao, L.; Feng, S.; Ci, H.; Ma, J.; Wang, L.; et al.
RNAi-Mediated Silencing of Atp6i and Atp6i Haplo insufficiency Prevents Both Bone Loss and Inflammation
in a Mouse Model of Periodontal Disease. PLoS ONE 2013, 8, e58599.
Int. J. Mol. Sci. 2019, 20, 3551 16 of 16
48. Chen, W.; Gao, B.; Hao, L.; Zhu, G.; Jules, J.; MacDougall, M.J.; Wang, J.; Han, X.; Zhou, X.; Li, Y.P. The silencing
of cathepsin K used in gene therapy for periodontal disease reveals the role of cathepsin K in chronic infection
and inflammation. J. Periodontal Res. 2016, 51, 647–660. [CrossRef]
49. Jiang, S.; Tang, K.; Chen, B.; Yan, F. Regenerative effect of hOPG gene-modified autologous PDLs in
combination with cell transplantation on periodontal defection in beagle dogs. Cytotechnology 2016, 68,
2613–2623. [CrossRef]
50. Zhu, Z.; Lee, C.S.; Tejeda, K.M.; Giannobile, W.V. Gene Transfer and Expression of Platelet-derived Growth
Factors Modulate Periodontal Cellular Activity. J. Dent. Res. 2001, 80, 892–897. [CrossRef]
51. Dunn, C.A.; Jin, Q.; Taba, M., Jr.; Franceschi, R.T.; Bruce Rutherford, R.; Giannobile, W.V. BMP gene delivery
for alveolar bone engineering at dental implant defects. Mol. Ther. 2005, 11, 294–299. [CrossRef]
52. Xiang, L.; Ma, L.; He, Y.; Wei, N.; Gong, P. Transfection with follicular dendritic cell secreted protein to affect
phenotype expression of human periodontal ligament cells. J. Cell. Biochem. 2014, 115, 940–948. [CrossRef]
53. Zhu, S.Y.; Wang, P.L.; Liao, C.S.; Yang, Y.Q.; Yuan, C.Y.; Wang, S.; Dissanayaka, W.L.; Heng, B.C.; Zhang, C.F.
Transgenic expression of ephrinB2 in periodontal ligament stem cells (PDLSCs) modulates osteogenic
differentiation via signaling crosstalk between ephrinB2 and EphB4 in PDLSCs and between PDLSCs and
preosteoblasts within co-culture. J. Periodontal Res. 2017, 52, 562–573. [CrossRef]
54. Logan, A.C.; Lutzko, C.; Kohn, D.B. Advances in lentiviral vector design for gene-modification of
hematopoietic stem cells. Curr. Opin. Biotechnol. 2002, 13, 429–436. [CrossRef]
55. Wang, Y.; Shang, S.; Li, C. Comparison of different kinds of non-viral vectors for gene delivery to human
periodontal ligament stem cells. J. Dent. Sci. 2015, 10, 414–422. [CrossRef]
56. Peng, L.; Cheng, X.; Zhuo, R.; Lan, J.; Wang, Y.; Shi, B.; Li, S. Novel gene-activated matrix with embedded
chitosan/plasmid DNA nanoparticles encoding PDGF for periodontal tissue engineering. J. Biomed. Mater.
Res. Part A. 2009, 90, 564–576. [CrossRef]
57. Chang, P.C.; Cirelli, J.A.; Jin, Q.; Seol, Y.J.; Sugai, J.V.; D’Silva, N.J.; Danciu, T.E.; Chandler, L.A.;
Sosnowski, B.A.; Giannobile, W.V. Adenovirus encoding human platelet-derived growth factor-B delivered
to alveolar bone defects exhibits safety and biodistribution profiles favorable for clinical use. Hum. Gene
Ther. 2009, 20, 486–496. [CrossRef]
58. Yang, C.; Liu, Y.; Li, C.; Zhang, B. Repair of mandibular defects by bone marrow stromal cells expressing the
basic fibroblast growth factor transgene combined with multi-pore mineralized Bio-Oss. Mol. Med. Rep.
2013, 7, 99–104. [CrossRef]
59. Plonka, A.B.; Khorsand, B.; Yu, N.; Sugai, J.V.; Salem, A.K.; Giannobile, W.V.; Elangovan, S. Effect of Sustained
PDGF Non-Viral Gene Delivery on Repair of Tooth-Supporting Bone Defects. Gene Ther. 2017, 24, 31–39.
[CrossRef]
60. Sugano, M.; Negishi, Y.; Endo-Takahashi, Y.; Hamano, N.; Usui, M.; Suzuki, R.; Maruyama, K.; Aramaki, Y.;
Yamamoto, M. Gene delivery to periodontal tissue using Bubble liposomes and ultrasound. J. Periodonal Res.
2014, 49, 398–404. [CrossRef]
61. Asa’ad, F.; Pagni, G.; Pilipchuk, S.P.; Giannì, A.B.; Giannobile, W.V.; Rasperini, G. 3D-Printed Scaffolds and
Biomaterials: Review of Alveolar Bone Augmentation and Periodontal Regeneration Applications. Int. J.
Dent. 2016, 2016, 1239842. [CrossRef]
62. Asa’ad, F.; Monje, A.; Larsson, L. Scaffolds in Periodontal Tissue Engineering. In Handbook of Tissue Engineering
Scaffolds:Volume One; Mozafari, M., Sefat, F., Atala, A., Eds.; Elsevier: Cambridge, UK, 2019; pp. 479–496.
63. Atasoy-Zeybek, A.; Kose, G.T. Gene Therapy Strategies in Bone Tissue Engineering and Current Clinical
Applications. Adv. Exp. Med. Biol. 2018, 4, 85–101.
64. Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; Le Deist, F.; Wulffraat, N.; McIntyre, E.; Radford, I.;
Villeval, J.L.; Fraser, C.C.; Cavazzana-Calvo, M.; et al. A serious adverse event after successful gene therapy
for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003, 348, 255–256. [CrossRef]
65. Luo, D.; Saltzman, W.M. Synthetic DNA delivery systems. Nat. Biotechnol. 2000, 18, 33–37. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
